International Non-Proprietary Name (INN): polydihydroxyphenylenethiosulfonate sodium
Dosage form: capsules
In 1 capsule:
Active ingredient: sodium polyhydroxyphenylene thiosulfonate (hypoxene®) 250 mg;
Excipients: gelatin, black iron oxide (E172), red iron oxide (E172), yellow iron oxide (E172), titanium dioxide (E171)
Hard dark brown gelatin capsules. The logo of the manufacturer is applied on the capsule with white paint (titanium dioxide). The content of the capsules is black powder, odorless or with a slight characteristic smell.
Pharmacological classification: Antihypoxic drug [Antihypoxants and antioxidants]
ATC code: N07XX
Pharmacological action: antihypoxic drug
Hypoxen belongs to the class of antihypoxants and antioxidants, which reduce oxygen consumption and increase the body’s ability to work in extreme situations. The drug has an antihypoxic effect by increasing the effectiveness of tissue respiration in conditions of hypoxia, especially in organs with a high level of metabolism (brain, heart muscle, liver).
Hypoxen provides a reduction in oxygen consumption with significant physical exertion, improved tissue respiration, a decrease in mental and physical fatigue, and the successful implementation of labor-intensive physical operations.
- to improve performance in extreme and adverse conditions, accompanied by a lack of oxygen (highlands, the conditions of the Arctic, underwater work, etc.);
- mental and physical strain, camera work and other intense stress, accompanied by chronic fatigue and fatigue;
- in the complex therapy of severe traumatic lesions, blood loss, extensive surgery, respiratory diseases (bronchial asthma, pneumonia, obstructive bronchitis);
- as part of the complex therapy of stable angina (prevention of angina attacks), arterial hypertension, chronic heart failure I and II functional class according to NYHA.
- individual intolerance;
- lactation period;
- hemorrhagic stroke.
Dosage and administration
Ingest before or during meals, with a small amount of liquid. Single dose for adults is 2–4 capsules. The maximum daily dose is 12 capsules.
The calculation of the daily dose per body weight is given in the table below.
|Body weight, kg||Daily dose, capsules|
Elimination of hypoxia that develops in extreme conditions (lung hypoventilation, highlands, underwater work, work at elevated temperatures, exercise)
One daily dose 30–60 minutes before the exercise.
Prolonged intense mental activity, chronic fatigue, short recovery period after an excessive physical exercise, trauma, surgical interventions
1/2 of the daily dose 2 times a day for 2-3 weeks. The treatment can be repeated with a break for 1-2 weeks.
Comprehensive treatment of pneumonia
1/2 of the daily dose 2 times a day, the course is 14 days.
Comprehensive treatment of obstructive bronchitis
1/2 of the daily dose 2 times a day, 2 courses of 14 days with an interval of 7 days.
Comprehensive treatment of bronchial asthma
1/2 of the daily dose 2 times a day, the course is 21–30 days with an interval of 10 days.
Comprehensive prevention of stable stenocardia
1/2 of the daily dose 2 times a day, the course is 15–30 days with an interval of 10 days.
Comprehensive treatment of hypertension
1/2 of the daily dose 2 times a day, the course is 10 days.
Comprehensive treatment of the heart failure
1/2 of the daily dose 2 times a day, the course is 10–14 days.
Possible: Allergic response.
Dry mouth, nausea and stomach discomfort, in rare cases – respiratory depression.
Stomach lavage, activated charcoal intake, symptomatic therapy.
Interaction with other drugs
Negative pharmaceutical, pharmacodynamic and pharmacokinetic interaction with other drugs have not been established. Incompatibility of the drug with other drugs has not been identified.
Pregnancy and lactation
The use of Hypoxen is contraindicated during pregnancy. If you need to take the drug during lactation, breastfeeding should be discontinued.
Parenteral application of the drug must be performed in sterile conditions. Due to the possibility of anaphylaxis, it is recommended to perform a trial injection (test for hypersensitivity).
Do not use an opaque solution or a solution containing particles.
After opening an ampoule, do not store any leftover solution.
Terms of release from pharmacy
Store in a dry dark place at temperatures no higher than 25°C. Keep out of reach of children.
4 years. Do not use beyond the expiration date printed on the package.
Valenta Pharm / Olifen Pharmaceutical Factory, Russia. https://www.valentapharm.com/eng/, https://www.olifen-corp.ru/